Related Experiment Video
Updated: Mar 9, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
Chaoqi Liu1, Jiao Lu1, Huiqun Tian1
1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei 443001, P.R. China.
Abstract:
Cytotoxic T lymphocyte dysfunction is frequently associated with PD‑L1/PD‑1 pathway activation, and is a principal obstacle in cancer therapy. In the present study, the mechanisms underlying the human papillomavirus (HPV)‑induced evasion of cervical cancer cells to the host immune system via the programmed death ligand 1/programmed death 1 (PD‑L1/PD‑1) signaling pathway was investigated. A significant increase in the expression of the HPV16E7 viral protein and PD‑L1 in cervical tissues was observed when compared with normal cervical tissues. In addition, a positive correlation between HPV16E7 and PD‑L1 expression was observed by immunohistochemical staining and reverse transcription‑polymerase chain reaction. Overexpressing HPV16E7 oncoprotein in the epithelial carcinoma of PC3 cells increased the expression level of the PD‑L1 protein and inhibited peripheral blood mononuclear cell (PBMC) proliferation and cytotoxic T lymphocyte (CTL) activity. Upon knockdown of HPV16E7 in HPV16‑associated CaSki cervical cancer cells with a relevant siRNA, a reduction in PD‑L1 protein expression was observed, as well as a significant increase in PBMC proliferation and CTL activity. A recombinant plasmid, MSCVPIG‑soluble PD‑1, was constructed and transfected into the CaSki cell line, and was co‑cultured with PBMCs. PBMC proliferation and CTL activity were observed to increase significantly. In conclusion, the results presented in the current study suggest that overexpression of PD‑L1, induced by HPV16E7, may be responsible for lymphocyte dysfunction. In addition, soluble PD‑1 may restore the function of tumor‑infiltrating lymphocytes by inhibiting the PD‑L1/PD‑1 signaling pathway. These results may provide a novel insight for immunotherapeutic approaches in the treatment of cervical cancer.
Insights
Human papillomavirus (HPV) E7 protein drives cervical cancer immune evasion by increasing PD-L1 expression, leading to T cell dysfunction. Restoring T cell activity may involve inhibiting the PD-L1/PD-1 pathway.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Cytotoxic T lymphocyte (CTL) dysfunction, often linked to PD-L1/PD-1 pathway activation, presents a major challenge in cancer therapy.
- Human papillomavirus (HPV) infection is a primary cause of cervical cancer and can contribute to immune evasion.
Purpose of the Study:
- To investigate the mechanisms by which HPV-induced cervical cancer cells evade the host immune system via the PD-L1/PD-1 signaling pathway.
- To explore the potential of targeting the PD-L1/PD-1 pathway for cervical cancer immunotherapy.
Main Methods:
- Comparative analysis of HPV16E7 and PD-L1 expression in cervical tissues using immunohistochemistry and RT-PCR.
- In vitro studies involving overexpression and knockdown of HPV16E7 in cancer cell lines (PC3, CaSki).
- Assessment of peripheral blood mononuclear cell (PBMC) proliferation and CTL activity.
- Transfection of CaSki cells with a soluble PD-1 expressing plasmid and co-culture with PBMCs.
Main Results:
- Significantly elevated HPV16E7 and PD-L1 expression in cervical cancer tissues compared to normal tissues, with a positive correlation between them.
- Overexpression of HPV16E7 increased PD-L1 levels, inhibiting PBMC proliferation and CTL activity.
- HPV16E7 knockdown reduced PD-L1 expression and enhanced PBMC proliferation and CTL activity.
- Soluble PD-1 treatment significantly increased PBMC proliferation and CTL activity.
Conclusions:
- HPV16E7-induced PD-L1 overexpression contributes to lymphocyte dysfunction in cervical cancer.
- Inhibiting the PD-L1/PD-1 pathway, potentially with soluble PD-1, can restore tumor-infiltrating lymphocyte function.
- These findings offer novel insights for developing immunotherapeutic strategies against cervical cancer.
More Related Videos
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
Related Concept Videos
Abnormal Proliferation
Mechanisms of Retrovirus-induced Cancers
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The Intrinsic Apoptotic Pathway
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...